International Clinical Trial: Brilliant-011- A Phase 1 HIV Vaccine Trial to evaluate the Safety and Immunogenicity of BG505 GT1.1 and 426c.Mod.Core-C4b Immunogens in a prime-boost Combination with Saponin/monophosphoryl lipid A nanoparticles (SMNP) Adjuvant in HIV-negative Adults

Geneva, May 4 -- International Clinical Trials Registry received information related to the study (PACTR202604518549022) titled 'Brilliant-011- A Phase 1 HIV Vaccine Trial to evaluate the Safety and Immunogenicity of BG505 GT1.1 and 426c.Mod.Core-C4b Immunogens in a prime-boost Combination with Saponin/monophosphoryl lipid A nanoparticles (SMNP) Adjuvant in HIV-negative Adults' on April 21.

Study Type: Interventional

Study Design: Parallel: different groups receive different interventions at same time during study,Randomised,Permuted block randomization,Allocation was determined by the holder of the sequence who is situated off site

Primary Sponsor: South African Medical Research Council

Condition:

HIV/AIDS

Recruitment Status: Not...